Exhibit 10.1


          Confidential Materials omitted and filed separately with the
        Securities and Exchange Commission. Asterisks denote omissions.




April 30, 2007

Lou Ferrari
Vice President, Sales
Ortho Biotech Inc.
430 Route 22 East
Bridgewater, New Jersey 08807-0914


RE:  First Amendment to the Co-Promotion Agreement between Millennium
     Pharmaceuticals, Inc. ("Millennium") and Ortho Biotech Inc.  ("OBI") dated
     October 25, 2006 (the "Co-Promotion Agreement")

Dear Lou:

The purpose of this letter ("Letter Amendment") is to amend the responsibilities
and obligations of OBI regarding attainment of reach and frequency minimums
under the Co-Promotion Agreement. Capitalized terms used herein but not defined
will have the same meaning given to them in the Co-Promotion Agreement.

This Letter Amendment shall be in effect upon the FDA's issuance of a notice of
approval of OBI's or its Affiliate's license to market and sell Doxil(R) for use
in combination with the Product for treatment of multiple myeloma ("Doxil
Approval") and shall continue in full force and effect until December 31, 2007
(the "Term").

The Parties agree as follows:

1.       OBI shall submit to the CPMC for review and approval, any advertising,
         promotional, (training and communication) materials of Doxil, including
         without limitation the core visual sales aid for the launch of the
         Doxil Approval, which are intended for use by Sales Representatives to
         Co-Promote the Product in combination with Doxil within the
         Co-Promotion Territory. During the Term, OBI shall use its best efforts
         to incorporate Millennium's comments on these materials in accordance
         with the review and approval provisions for Core Promotional Materials
         as set forth in Section 2.4.1 of the Co-Promotion Agreement.

2.       The Co-Promotion Agreement shall be amended by replacing the defined
         terms Call, First Position Call and Second Position Call with the
         definitions set forth below. These revised definitions will be in
         effect during the Term, and thereafter,


<PAGE>


         the terms Call, First Position Call and Second Position Call will be
         defined as set forth under the Co-Promotion Agreement as of its
         effective date.

            a.    "CALL" means an in-person presentation of the Product made by
                  a Sales Representative or the Product in combination with
                  Doxil made by a Sales Representative using the materials
                  approved by the CPMC in paragraph 1 above, to a MLNM Target
                  during which the Sales Representative describes the Product in
                  a fair and balanced manner consistent with the requirements of
                  the Agreement and Applicable Law and in a manner that is
                  customary in the industry for the purpose of promoting a
                  prescription pharmaceutical product.  "Calls" shall be deemed
                  to include only full sales presentations and shall not be
                  deemed to include "reminder" details or e-details, in each
                  case as such terms are generally understood in the
                  pharmaceutical industry, or any presentations made at
                  conventions, consulting programs or similar gatherings.

            b.    "FIRST POSITION CALL" shall mean a Call in which at least [**]
                  percent ([**]%) of the presentation is dedicated solely to the
                  Product or the Product in combination with Doxil, each in
                  accordance with the Co-Promotion Plan and in which the Product
                  or the Product in combination with Doxil is the first product
                  presented to the First Position Target.

            c.    "SECOND POSITION CALL" shall mean (a) a Call in which at least
                  [**] percent ([**]%) of the presentation is dedicated solely
                  to the Product or the Product in combination with Doxil, each
                  in accordance with the Co-Promotion Plan and in which the
                  Product or the Product in combination with Doxil is at least
                  the second product presented to the Second Position Target; or
                  (b) a Call in which at least [**] percent ([**]%) of the
                  presentation is dedicated solely to the Product or the Product
                  in combination with Doxil, each in accordance with the
                  Co-Promotion Plan and in which the Product or the Product in
                  combination with Doxil is the first product presented to the
                  Second Position Target.

Except as otherwise expressly modified by this Letter Amendment, the
Co-Promotion Agreement shall remain in full force and effect in accordance with
its terms.

Please acknowledge your acceptance of the terms set forth above by
countersigning this Letter Amendment where indicated below and returning a
signed copy to my attention.


<PAGE>


Sincerely,

Millennium Pharmaceuticals, Inc.

By:    /s/ GRANT C. BOGLE

Title: SVP - Sales and Marketing

Date:  4/30/07


AGREED TO AND ACCEPTED:
Ortho Biotech Products, L.P.

By:    /s/ MICHAEL YOUNG

Title: VP ONCOLOGY

Date:  5-2-07


cc:
Joaquin Duato
President
Ortho Biotech Products, L.P.